Celularity Inc. (CELU) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.25
↓-48% vs avg
5yr avg: 4.30
30Y Low1.0·High10.8
ROE
↑
-232.5%
↑-41% vs avg
5yr avg: -164.4%
30Y Low-308%·High10%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CELU Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Celularity Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $26M | $46M | $44M | $193M | $343M | $203M | $238M | — |
| Enterprise Value | $94M | $114M | $109M | $245M | $337M | $179M | $237M | — |
| P/E Ratio → | -0.34 | — | — | 13.62 | — | — | — | — |
| P/S Ratio | 0.47 | 0.84 | 1.93 | 10.75 | 16.09 | 14.19 | 11.23 | — |
| P/B Ratio | 2.25 | 5.15 | 1.07 | 0.97 | 3.45 | 10.83 | 1.72 | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CELU EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.10 | 4.80 | 13.62 | 15.81 | 12.53 | 11.23 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
CELU Profitability
Margins and return-on-capital ratios measuring operating efficiency
Celularity Inc. earns an operating margin of -70.7%. Operating margins have expanded from -142.4% to -70.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -232.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.4% | 72.4% | 29.7% | -9.4% | 54.8% | 65.5% | 70.1% | 62.7% |
| Operating Margin | -70.7% | -70.7% | -844.4% | -142.4% | -511.2% | -1064.0% | -1249.0% | -0.0% |
| Net Profit Margin | -106.8% | -106.8% | -862.0% | 79.0% | -469.3% | -1458.4% | -1001.9% | -0.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -232.5% | -232.5% | -163.7% | 9.5% | -169.5% | -266.0% | -307.7% | — |
| ROA | -41.9% | -41.9% | -72.0% | 3.5% | -23.7% | -43.7% | -81.3% | -4.4% |
| ROIC | -31.4% | -31.4% | -80.9% | -11.2% | -185.1% | -171.6% | -287.5% | — |
| ROCE | -49.3% | -49.3% | -92.5% | -7.0% | -27.5% | -33.6% | -105.5% | — |
CELU Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $68M ($69M total debt minus $738000 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 7.79 | 7.79 | 1.60 | 0.33 | 0.31 | 1.64 | 0.20 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.03 |
| Net Debt / Equity | — | 7.71 | 1.59 | 0.26 | -0.06 | -1.26 | -0.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 0.03 |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.12 | -6.12 | -63.78 | — | -34.39 | -64.54 | — | — |
CELU Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.38x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.54x to 0.38x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | 0.38 | 0.29 | 0.54 | 2.25 | 2.70 | 1.78 | 0.16 |
| Quick Ratio | 0.28 | 0.28 | 0.21 | 0.45 | 1.89 | 2.56 | 1.63 | -23.32 |
| Cash Ratio | 0.01 | 0.01 | 0.00 | 0.22 | 1.42 | 2.04 | 1.36 | 0.16 |
| Asset Turnover | — | 0.41 | 0.16 | 0.04 | 0.05 | 0.03 | 0.04 | 710.49 |
| Inventory Turnover | 2.77 | 2.77 | 2.78 | 3.70 | 1.01 | 1.28 | 1.96 | 1.85 |
| Days Sales Outstanding | — | 91.26 | 194.24 | 141.45 | 89.53 | 167.44 | 53.13 | 81.49 |
CELU Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Celularity Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 7.3% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — |
| Shares Outstanding | — | $22M | $18M | $15M | $7M | $2M | $2M | $4M |
Peer Comparison
Compare CELU with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CELUYou | $26M | -0.3 | — | — | 72.4% | -70.7% | -232.5% | -31.4% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 SANA | $918M | -3.0 | — | — | — | — | -99.2% | -86.1% | — |
 ALLO | $521M | -2.6 | — | — | — | — | -53.4% | -41.7% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 PGEN | $1B | -8.8 | — | — | -8.7% | -3440.2% | -160.8% | -152.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See CELU's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELU Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELU vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonCELU — Frequently Asked Questions
Quick answers to the most common questions about buying CELU stock.
What is Celularity Inc.'s P/E ratio?
Celularity Inc.'s current P/E ratio is -0.3x. The historical average is 13.6x.
What is Celularity Inc.'s ROE?
Celularity Inc.'s return on equity (ROE) is -232.5%. The historical average is -188.3%.
Is CELU stock overvalued?
Based on historical data, Celularity Inc. is trading at a P/E of -0.3x. Compare with industry peers and growth rates for a complete picture.
What are Celularity Inc.'s profit margins?
Celularity Inc. has 72.4% gross margin and -70.7% operating margin.